Pulmonx Corp Ordinary Shares LUNG
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.46
- Day Range
- $1.40–1.49
- 52-Week Range
- $1.13–3.88
- Bid/Ask
- $1.47 / $1.51
- Shares Outstanding
- 42.24M
- Market Cap
- $62.51M
- Volume/Avg
- 191,629 / 484,864
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.69
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 296
- Website
- https://www.pulmonx.com
Valuation
|
Metric
|
LUNG
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.37 |
Price/Sales | 0.69 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LUNG
|
|---|---|
Quick Ratio | 3.85 |
Current Ratio | 4.91 |
Interest Coverage | −15.33 |
Quick Ratio
LUNG
Profitability
|
Metric
|
LUNG
|
|---|---|
Return on Assets (Normalized) | −27.24% |
Return on Equity (Normalized) | −60.88% |
Return on Invested Capital (Normalized) | −30.85% |
Return on Assets
LUNG
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|%S!p&% | LOCK|KSCK | $155B | |||
| Stryker Corp
SYK
| LOCK|#y&rmvj | LOCK|@x | $119B | |||
| Medtronic PLC
MDT
| LOCK|vPtPxl? | LOCK|P^xr< | $102B | |||
| Boston Scientific Corp
BSX
| LOCK|bp@#S&< | LOCK|QP@ym | $63B | |||
| Edwards Lifesciences Corp
EW
| LOCK|#&DD#Hgw | LOCK|Dz#ry | $52B | |||
| DexCom Inc
DXCM
| LOCK|v%Q#Q$< | LOCK|N?^w | $29B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|f#&vysS | LOCK|QM | $28B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|@#$ | LOCK|LY | $25B | |||
| Steris PLC
STE
| LOCK|&d&<?&! | LOCK|kCR^ | $20B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|h$HZPww% | LOCK|J&% | $18B |
United States